Solutions
About Us
Insights
Careers
Contact us
Contact Us
Customer Support
Customer Support

Tezepelumab can Restore Normal Lung Function in Patients with Severe, Uncontrolled Asthma: Pooled Results from the PATHWAY and NAVIGATOR Studies. Pavord ID, Brightling CE, Korn S, Martin NL, Ponnarambil SS, Molfino NA, Parnes JR, Ambrose CS. Pulm Ther. 2025

Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study. Wheatley-Price P, Navani V, Pabani A, Routy B, Snow S, Denault MH, Kim Y, Syed I, Devost N, Hui D, Qadeer RA, Arora P, Velummailum R, Springford A, McKibbon C, Ho C. Lung Cancer. 2025

Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation. Chopra D, Lan Z, Waterhouse DM, Wolf J, Felip E, Moradian H, Karim N, Obiozor C, Stollenwerk B. Adv Ther. 2025

Epidemiology, patient management, and survival outcomes in resected patients with non-metastatic non-small cell lung cancer: a nationwide real-world study. Renaud S, Casabianca P, Diez-Andreu P, Chartier M, Gaudin AF, Bugnard F, Bénard S, Cotté FE, Chouaid C. BMC Cancer. 2025

Elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison. Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, Aydin D, Cruz IP, Hlavacek P. J Comp Eff Res. 2025

Impact of Seton Use on Clinical, Patient-Reported, and Healthcare Resource Utilization Outcomes in Complex Crohn’s Perianal Fistulas: A Systematic Literature Review. White I, Karki C, Geransar P, Leisle L, Junker S, Fleshner P. Inflamm Bowel Dis. 2025

Real-world experiences of adult individuals or caregivers of children who received teplizumab treatment in stage 2 type 1 diabetes. O’Donnell HK, Simmons KM, Gitelman SE, Dex T, Hill R, Wieloch M, Zaccai J, D’Souza J, Ginchereau Sowell F, Turnbull J, Hood KK. Diabetes Obes Metab. 2025

First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial. Jänne PA, Wang BC, Cho BC, Zhao J, Li J, Hochmair M, Peters S, Besse B, Pavlakis N, Neal JW, Kato T, Wu YL, Nguyen D, Lin J, Lin J, Vranceanu F, Szumski A, Lin HM, Fram RJ, Mok TSK. J Clin Oncol. 2025

Matching-Adjusted Indirect Comparison of Elranatamab versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma: Updated Results. Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, Aydin D, Perez Cruz I, Hlavacek P. J Blood Med. 2025

Impact of age and time since diagnosis on thrombosis risk in myeloproliferative neoplasm patients: A nationwide register-based matched cohort study. Batyrbekova N, Hultcrantz M, Ravn Landtblom A, Szulkin R, Dickman PW, Andersson TM, Syriopoulou E. Br J Haematol. 2025